IMNM

Immunome Stock Analysis

AI Rating

Neutral
  • Quality1/10
  • Growth↑ 7/10
  • Momentum↑ 9/10
Immunome sales and earnings growth
IMNM Growth
Good
  • Revenue Y/Y↓ -4.44%
  • EPS Y/Y↑ 63.63%
  • FCF Y/Y↓ -107.19%
Immunome gross and profit margin trends
IMNM Profitability
Low
  • Gross margin ↑ 100.00%
  • EPS margin↓ -2301.30%
  • ROIC↓ -373.20%
Immunome net debt vs free cash flow
IMNM Risk
Great
  • Debt / Equity↓ 0.0
  • Debt / FCF↓ 0.0
  • Interest coverage↓ NA

Immunome stock volatility is in-line with the overall market. We give it a Great risk rating.

More Biotechnology stocks ↗